{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "alveolosphere",
      "drug screening",
      "lung",
      "organoid",
      "stem cell niche"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34038715",
  "DateCompleted": {
    "Year": "2021",
    "Month": "06",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "05",
        "Day": "19"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.celrep.2021.109218",
      "S2211-1247(21)00569-6"
    ],
    "Journal": {
      "ISSN": "2211-1247",
      "JournalIssue": {
        "Volume": "35",
        "Issue": "10",
        "PubDate": {
          "Year": "2021",
          "Month": "Jun",
          "Day": "08"
        }
      },
      "Title": "Cell reports",
      "ISOAbbreviation": "Cell Rep"
    },
    "ArticleTitle": "Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening.",
    "Pagination": {
      "StartPage": "109218",
      "MedlinePgn": "109218"
    },
    "Abstract": {
      "AbstractText": [
        "Although the main cellular target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be alveolar cells, the absence of their tractable culture system precludes the development of a clinically relevant SARS-CoV-2 infection model. Here, we establish an efficient human alveolosphere culture method and sphere-based drug testing platform for SARS-CoV-2. Alveolospheres exhibit indolent growth in a Wnt- and R-spondin-dependent manner. Gene expression, immunofluorescence, and electron microscopy analyses reveal the presence of alveolar cells in alveolospheres. Alveolospheres express ACE2 and allow SARS-CoV-2 to propagate nearly 100,000-fold in 3\u00a0days of infection. Whereas lopinavir and nelfinavir, protease inhibitors used for the treatment of human immunodeficiency virus (HIV) infection, have a modest anti-viral effect on SARS-CoV-2, remdesivir, a nucleotide prodrug, shows an anti-viral effect at the concentration comparable with the circulating drug level. These results demonstrate the validity of the alveolosphere culture system for the development of therapeutic agents to combat SARS-CoV-2."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 The Author(s). Published by Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Ebisudani",
        "ForeName": "Toshiki",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Sugimoto",
        "ForeName": "Shinya",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Viral Infection I, Department of Infection Control and Immunology, \u014cmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan."
          }
        ],
        "LastName": "Haga",
        "ForeName": "Kei",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Mitsuishi",
        "ForeName": "Akifumi",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Viral Infection I, Department of Infection Control and Immunology, \u014cmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan."
          }
        ],
        "LastName": "Takai-Todaka",
        "ForeName": "Reiko",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Fujii",
        "ForeName": "Masayuki",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Toshimitsu",
        "ForeName": "Kohta",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Hamamoto",
        "ForeName": "Junko",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Sugihara",
        "ForeName": "Kai",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Hishida",
        "ForeName": "Tomoyuki",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Thoracic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Asamura",
        "ForeName": "Hisao",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan."
          }
        ],
        "LastName": "Fukunaga",
        "ForeName": "Koichi",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pulmonary Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: hiroyukiyasuda@a8.keio.jp."
          }
        ],
        "LastName": "Yasuda",
        "ForeName": "Hiroyuki",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratory of Viral Infection I, Department of Infection Control and Immunology, \u014cmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: katayama@lisci.kitasato-u.ac.jp."
          }
        ],
        "LastName": "Katayama",
        "ForeName": "Kazuhiko",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Organoid Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; Coronavirus Task Force, Keio University School of Medicine, Tokyo 160-8582, Japan. Electronic address: t.sato@keio.jp."
          }
        ],
        "LastName": "Sato",
        "ForeName": "Toshiro",
        "Initials": "T"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cell Rep",
    "NlmUniqueID": "101573691"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "Proto-Oncogene Proteins c-akt"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "drug effects",
        "metabolism",
        "virology"
      ],
      "DescriptorName": "Alveolar Epithelial Cells"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "metabolism",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cells, Cultured"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Evaluation, Preclinical"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Proto-Oncogene Proteins c-akt"
    },
    {
      "QualifierName": [
        "drug effects",
        "growth & development",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Spheroids, Cellular"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Wnt Signaling Pathway"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "Declaration of interests T.S. is an inventor on several patents related to organoid culture."
}